-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
Boston Scientific delivered solid Q1 2026 results with net sales of $5.203B (+11.6% reported, +9.4% organic), continuing double-digit growth though at a more normalized pace versus exceptional 2025 levels. The quarter showed broad-based momentum with Cardiovascular generating $3.503B (+13.5% reported, +11.2% organic) and MedSurg contributing $1.701B (+7.8% reported, +5.7% organic). We view sustained Cardiovascular growth favorably, led by FARAPULSE adoption and structural heart solutions, underscoring leadership in high-growth markets. Management provided 2026 guidance with organic sales growth of 6.5%-8.0% and adjusted EPS of $3.34-$3.41, implying further deceleration but maintaining an above-market trajectory. We believe U.S. market strength with $3.284B in revenues (+10.9%) and standout Neuromodulation performance (+17.4% growth) support our positive outlook, while the active innovation pipeline with CHAMPION-AF trial successes positions Boston Scientific to sustain its competitive advantages.